| BACKGROUND:Glioma is a tumor originating from glial cells and is the most common primary intracranial tumor,and its incidence has been increasing year by year in recent years.High-grade glioma has attracted special attention because of its high mortality,but the current treatment effect is not ideal.Recently,domestic and foreign studies have revealed some molecular markers for the efficacy and prognosis of glioma,but they are still far from meeting clinical needs.Studies have shown that RHBDD2(rhomboid domain protein)is highly expressed in advanced breast cancer and colorectal cancer,and found that it is highly expressed in brain,spinal cord and other tissues in early stages,but its expression and clinical significance in glioma are not clear.In this experiment,the expression level of RHBDD2 in glioma and its relationship with clinicopathological characteristics and its value in prognosis were investigated by immunohistochemistry.OBJECTIVE:To explore the expression level of RHBDD2 in glioma and its relationship with clinicopathological features and its value in prognosis of patients.METHODS:A total of 86 specimens of patients with brain glioma surgically removed in Henan Province People’s Hospital from December 2018 to October 2020 were collected and made into wax blocks.The expression level of RHBDD2 was detected by immunohistochemistry,and the relationship between the expression of RHBDD2 and clinicopathological features and its prognostic value in patients were analyzed.RESULTS:A total of 81 patients with glioma tumor tissue completed the immunohistochemical readings.Among them,60 were high-grade gliomas and 21 were low-grade gliomas.The result obtained by multiplying the immunohistochemical staining intensity by the staining range score was determined as the final immunohistochemical score,where 0-6 points were defined as low expression,and 6-12 points were defined as high expression.1.The high expression rate of RHBDD2 in high-level glioma tumor tissues was 66.67%(40/60),and the difference was statistically significant compared with 10 cases of normal tissues around the tumor(P=0.029).2.The high expression rate of RHBDD2 in glioma tumor tissue samples was 56.79%(46/81).Among the patients with low-grade gliomas,the high expression rate of RHBDD2 was 28.57%(6/21),and in the patients with high-grade gliomas,the high expression rate of RHBDD2 was 66.67%(40/60).Tumor grade and RHBDD2 expression were compared by chi-square test,and the difference was statistically significant(χ~2= 9.200,P=0.002).3.There was no significant difference between the expression of RHBDD2 in tumor tissue and the patient’s age,gender,P53 mutation,IDH1 mutation,ATRX mutation,Ki67 expression and tumor diameter(P>0.05).4.Kaplan-Meier survival analysis was used to analyze the relationship between the expression of RHBDD2 and the prognosis of glioma patients.The median Progression-free survival(m PFS)and median Overall Survival(m OS)of patients in the high expression group were shorter than those in the low expression group(m PFS: 9.5 months vs 12.0 months;m OS: 13.5 months vs 20.0 months).5.COX regression analysis showed that the expression of RHBDD2 in glioma patients was associated with overall survival(HR=1.992,95%CI confidence interval=1.014-3.915,P=0.046)and progression-free survival of patients(HR=2.142,95%CI confidence interval=1.091-4.204,P=0.027),and the prognosis of glioma patients was related to tumor grade,age,IDH1 mutation status,and Ki67 expression status,and the difference was statistically significant(P<0.05).CONCLUSION:1.The expression of RHBDD2 is closely related to the grade of glioma,and its expression issignificantly increased in high-grade glioma.2.The high expression of RHBDD2 indicates that the prognosis of glioma patients is poor,andthe median PFS and median OS are both poor. |
PDF Full Text Request